Page 129 - Read Online

Gomaa et al. Advanced HCC: current and potential therapies

study by the Gruppo Oncologico dell’Italia Meridionale (prot. GOIM with unresectable hepatocellular carcinoma: a propensity score
2705). J Clin Oncol 2011;29:225. matching study. J Dig Dis 2013;14:181-90.
62. Liu Y, Yue H, Xu S, Wang F, Ma N, Li K, Qiao L, Wang J. First- 75. Choi GH, Shim JH, Kim MJ, Ryu MH, Ryoo BY, Kang YK, Shin
line gemcitabine and oxaliplatin (GEMOX) plus sorafenib, followed YM, Kim KM, Lim YS, Lee HC. Sorafenib alone versus sorafenib
by sorafenib as maintenance therapy, for patients with advanced combined with transarterial chemoembolization for advanced-stage
hepatocellular carcinoma: a preliminary study. Int J Clin Oncol hepatocellular carcinoma: results of propensity score analyses.
2015;20:952-9. Radiology 2013;269:603-11.
63. Assenat E, Boige V, Thezenas S, Pageaux GP, Peron JM, Becouarn 76. Qu XD, Chen CS, Wang JH, Yan ZP, Chen JM, Gong GQ, Liu QX,
Y, Dahan L, Merle P, Blanc JF, Bouche O, Ramdani M, Mazard Luo JJ, Liu LX, Liu R, Qian S. The efficacy of TACE combined
T, Bleuse JP, Ychou M. Sorafenib (S) alone versus S combined sorafenib in advanced stages hepatocellullar carcinoma. BMC Cancer
with gemcitabine and oxaliplatin (GEMOX) in first-line treatment 2012;12:263.
of advanced hepatocellular carcinoma (HCC): final analysis of 77. Ohki T, Sato K, Yamagami M, Ito D, Yamada T, Kawanishi K,
the randomized phase II GONEXT trial (UNICANCER/FFCD Kojima K, Seki M, Toda N, Tagawa K. Efficacy of transcatheter
PRODIGE 10 trial). J Clin Oncol 2013;31 suppl 15:abstr4028. arterial chemoembolization followed by sorafenib for intermediate/
64. Yau T, Cheung FY, Lee F, Choo SP, Wong H, Toh HC, Leung A, advanced hepatocellular carcinoma in patients in Japan: a
Chan P, Yau T, Wong J. A multicenter phase II study of sorafenib, retrospective analysis. Clin Drug Investig 2015;35:751-9.
capecitabine, and oxaliplatin (SECOX) in patients with advanced 78. Hu H, Duan Z, Long X, Hertzanu Y, Shi H, Liu S, Yang Z. Sorafenib
hepatocellular carcinoma: final results of Hong Kong-Singapore combined with transarterial chemoembolization versus transarterial
Hepatocellular Carcinoma Research Collaborative Group study. J chemoembolization alone for advanced-stage hepatocellular carcinoma:
Clin Oncol 2013;31 suppl 15:abstr4117. a propensity score matching study. PLoS One 2014;9:e96620.
65. Abou-Alfa GK, Niedzwieski D, Knox JJ, Kaubisch A, Posey J, 79. Zhang L, Hu P, Chen X, Bie P. Transarterial chemoembolization
Tan BR, Kavan P, Goel R, Murray JJ, Bekaii-Saab TS. Phase III (TACE) plus sorafenib versus TACE for intermediate or advanced
randomized study of sorafenib plus doxorubicin versus sorafenib stage hepatocellular carcinoma: a meta-analysis. PLoS One
in patients with advanced hepatocellular carcinoma (HCC): 2014;9:e100305.
CALGB80802 (Alliance). Am Soc Clin Oncol 2016;suppl 4:abstr192. 80. Kudo M, Matsui O, Izumi N, Iijima H, Kadoya M, Imai Y, Okusaka T,
66. Kudo M, Ueshima K, Yokosuka O, Obi S, Izumi N, Aikata H, Miyayama S, Tsuchiya K, Ueshima K. JSH consensus-based clinical
Nagano H, Hatano E, Sasaki Y, Hino K. Prospective randomized practice guidelines for the management of hepatocellular carcinoma:
controlled phase III trial comparing the efficacy of sorafenib versus 2014 update by the Liver Cancer Study Group of Japan. Liver Cancer
sorafenib in combination with low-dose cisplatin/fluorouracil 2014;3:458-68.
hepatic arterial infusion chemotherapy in patients with advanced 81. Group KLCS. 2014 Korean Liver Cancer Study Group-National
hepatocellular carcinoma. J Hepatol 2016;64:S209-10. Cancer Center Korea practice guideline for the management of
67. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. Ko J Radiol 2015;16:465-522.
hepatocellular carcinoma. J Hepatol 2012;56:908-43. 82. Kasai K, Sawara K, Suzuki K. Combination therapy of intra-arterial
68. Bruix J, Sherman M. Management of hepatocellular carcinoma. 5-fluorouracil and systemic pegylated interferon alpha-2b for
Hepatology 2005;42:1208-36. advanced hepatocellular carcinoma. Int J Clin Oncol 2011;16:221-9.
69. Kokudo N, Hasegawa K, Akahane M, Igaki H, Izumi N, Ichida T, 83. Song DS, Song MJ, Bae SH, Chung WJ, Jang JY, Kim YS, Lee
Uemoto S, Kaneko S, Kawasaki S, Ku Y. Evidence-based clinical SH, Park JY, Yim HJ, Cho SB, Park SY, Yang JM. A comparative
practice guidelines for hepatocellular carcinoma: the Japan society study between sorafenib and hepatic arterial infusion chemotherapy
of hepatology 2013 update (3rd JSH-HCC guidelines). Hepatol Res for advanced hepatocellular carcinoma with portal vein tumor
2015;45:238-46. thrombosis. J Gastroenterol 2015;50:445-54.
70. Kudo M, Izumi N, Kokudo N, Matsui O, Sakamoto M, Nakashima 84. Salem R, Mazzaferro V, Sangro B. Yttrium 90 radioembolization for
O, Kojiro M, Makuuchi M; HCC Expert Panel of Japan Society of the treatment of hepatocellular carcinoma: biological lessons, current
Hepatology. Management of hepatocellular carcinoma in Japan: challenges, and clinical perspectives. Hepatology 2013;58:2188-97.
consensus-based clinical practice guidelines proposed by the Japan Society 85. Salem R, Lewandowski RJ, Mulcahy MF, Riaz A, Ryu RK, Ibrahim
of Hepatology (JSH) 2010 updated version. Dig Dis 2011;29:339-64. S, Atassi B, Baker T, Gates V, Miller FH, Sato KT, Wang E, Gupta
71. Chung GE, Lee JH, Kim HY, Hwang SY, Kim JS, Chung JW, Yoon R, Benson AB, Newman SB, Omary RA, Abecassis M, Kulik L.
JH, Lee HS, Kim YJ. Transarterial chemoembolization can be safely Radioembolization for hepatocellular carcinoma using Yttrium-90
performed in patients with hepatocellular carcinoma invading the microspheres: a comprehensive report of long-term outcomes.
main portal vein and may improve the overall survival. Radiology Gastroenterology 2010;138:52-64.
2011;258:627-34. 86. Salem R, Lewandowski RJ, Kulik L, Wang E, Riaz A, Ryu RK, Sato
72. Martin R, Keck G, Robbins K, Strnad B, Dubel G, Longares J, KT, Gupta R, Nikolaidis P, Miller FH, Yaghmai V, Ibrahim SM,
Padr R, Narayanan G. Evaluation of sorafenib in combination with Senthilnathan S, Baker T, Gates VL, Atassi B, Newman S, Memon
doxorubicin-loaded DC bead as a combination treatment option for K, Chen R, Vogelzang RL, Nemcek AA, Resnick SA, Chrisman
HCC. ASCO Gastrointestinal Cancers Symposium 2010;suppl:abstr HB, Carr J, Omary RA, Abecassis M, Benson AB 3rd, Mulcahy
216. MF. Radioembolization results in longer time-to-progression and
73. Muhammad A, Dhamija M, Vidyarthi G, Amodeo D, Boyd W, reduced toxicity compared with chemoembolization in patients with
Miladinovic B, Kumar A. Comparative effectiveness of traditional hepatocellular carcinoma. Gastroenterology 2011;140:497-507.
chemoembolization with or without sorafenib for hepatocellular 87. Sangro B, Carpanese L, Cianni R, Golfieri R, Gasparini D, Ezziddin
carcinoma. World J Hepatol 2013;5:364-71. S, Paprottka PM, Fiore F, Van Buskirk M, Bilbao JI, Ettorre GM,
74. Bai W, Wang YJ, Zhao Y, Qi XS, Yin ZX, He CY, Li RJ, Wu Salvatori R, Giampalma E, Geatti O, Wilhelm K, Hoffmann RT,
KC, Xia JL, Fan DM, Han GH. Sorafenib in combination with Izzo F, Inarrairaegui M, Maini CL, Urigo C, Cappelli A, Vit A,
transarterial chemoembolization improves the survival of patients Ahmadzadehfar H, Jakobs TF, Lastoria S. Survival after yttrium-90
Hepatoma Research ¦ Volume 3 ¦ June 15, 2017 121